Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARULIGHT: Reduced Dose Darunavir in Virologically Suppressed HIV-1 Patients
NCT02384967Phase 2Completed
- Sponsor
- ANRS
- Start
- Mar 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darunavir in human immunodeficiency virus infection (HIV), sponsored by ANRS. Primary endpoint: Proportion of patients with therapeutic success (no virological failure) at 48 weeks. Started Mar 2015; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02384967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384967.